Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Trial Details

NCT ID

NCT06431685

Phase

PHASE1

Sponsor

Sichuan University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Whole Brain Low Dose Radiotherapy
• Pemetrexed
• Sintilimab
• Chemotherapy

Locations (sample)

• Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

• ≥ 18 years old and ≤ 75 years old;
• Patients with a definite diagnosis of leptomeningeal metastasis by cerebrospinal fluid cytology, or patients with clinical diagnosis combined with …
• Patients with a clear history of lung carcinoma, including histopathological diagnosis or a combination of cytopathology and imaging, and failure o…
• Efficacy of extracranial lesions SD;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.